Fig. 4From: Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort studyThe best change of intracranial lesions in two patients with baseline intracranial lesions over 1 cm (A) baseline intracranial lesion of patient 1; B best change of intracranial lesion of patient 1; C baseline intracranial lesion of patient 2; D best change of intracranial lesion of patient 2Back to article page